Deutsche Bank set a €104.00 ($120.93) price target on Merck KGaA (FRA:MRK) in a report issued on Tuesday morning, Borsen Zeitung reports. The firm currently has a neutral rating on the healthcare company’s stock.

MRK has been the subject of a number of other reports. Morgan Stanley set a €96.00 ($111.63) price target on Merck KGaA and gave the stock a neutral rating in a report on Tuesday, September 10th. Credit Suisse Group set a €110.00 ($127.91) price target on Merck KGaA and gave the stock a buy rating in a report on Friday, September 6th. Sanford C. Bernstein set a €114.00 ($132.56) price target on Merck KGaA and gave the stock a neutral rating in a report on Wednesday, October 9th. Bank of America set a €110.00 ($127.91) price target on Merck KGaA and gave the stock a neutral rating in a report on Friday, September 13th. Finally, Barclays set a €82.00 ($95.35) price target on Merck KGaA and gave the stock a sell rating in a report on Monday, October 14th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of €101.78 ($118.35).

Shares of MRK stock traded down €3.60 ($4.19) during trading hours on Tuesday, reaching €106.15 ($123.43). 1,028,425 shares of the company’s stock were exchanged. Merck KGaA has a fifty-two week low of €76.60 ($89.07) and a fifty-two week high of €115.00 ($133.72). The business has a fifty day moving average price of €105.33 and a 200-day moving average price of €96.85.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Featured Article: What does an inverted yield curve signify?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.